Cargando…
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
Thyroid eye disease is a disabling autoimmune disease associated with orbital inflammation and tissue remodeling which can result in significant proptosis, leading to visual alterations and is potentially sight threatening. Current evidence indicates that autoantibodies to the insulin-like growth fa...
Autor principal: | Douglas, Raymond S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367366/ https://www.ncbi.nlm.nih.gov/pubmed/30575804 http://dx.doi.org/10.1038/s41433-018-0321-y |
Ejemplares similares
-
Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022) -
OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020) -
Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease
por: Xin, Yan, et al.
Publicado: (2021) -
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022) -
Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021)